Asia Pacific Ophthalmology Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2023 –2030 |
 Marktgröße (Basisjahr) | USD 10,224.97 Million |
 Marktgröße (Prognosejahr) | USD 18,071.10 Million |
 CAGR |
% |
| Wichtige Marktteilnehmer |
>Markt für Augenheilkunde im asiatisch-pazifischen Raum nach Produkt (Geräte, Medikamente und andere), Krankheiten ( Glaukom , Katarakt, altersbedingte Makuladegeneration, entzündliche Erkrankungen, Refraktionsstörungen und andere), Verschreibungsmodus (Generika und Marken), Medikamententyp (verschreibungspflichtig und rezeptfrei), Verabreichungsweg (oral, topisch, injizierbar, lokal am Auge und andere), Endbenutzer (Krankenhäuser, Kliniken, häusliche Pflege und andere), Vertriebskanal (direkte Ausschreibung, Einzelhandelsverkauf und andere) – Branchentrends und Prognose bis 2030.
Asien-Pazifik-Markt für Augenheilkunde – Analyse und Größe
Einer der Hauptfaktoren, die das Wachstum des Augenheilkundemarktes vorantreiben, ist die zunehmende Verbreitung von Augenerkrankungen und Augenschmerzen. Die fortlaufenden klinischen Studien, die von mehreren Pharmaunternehmen durchgeführt werden, um Behandlungsmöglichkeiten zu verbessern, und die Belastung durch bestimmte Toxine oder Umweltveränderungen erhöhen die Anzahl augenheilkundlicher Produkte und führen zu einer Marktexpansion. Der Markt wird auch durch einen zunehmend unhygienischen und sitzenden Lebensstil sowie einen Anstieg traumatischer Verletzungen beeinflusst. Die hohen Kosten und Risiken im Zusammenhang mit Augenoperationen und -behandlungen, der Mangel an Krankenversicherung in der Bevölkerung, insbesondere in Entwicklungsländern, und die lange Zeitspanne für die Herstellung und Formulierung augenheilkundlicher Medikamente wirken sich jedoch im Prognosezeitraum als hemmende Faktoren für den Augenheilkundemarkt im asiatisch-pazifischen Raum aus.
Der Markt für Augenheilkunde im asiatisch-pazifischen Raum wird im Prognosezeitraum von 2023 bis 2030 voraussichtlich ein Marktwachstum verzeichnen. Data Bridge Market Research analysiert, dass der Markt im Prognosezeitraum von 2023 bis 2030 mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 7,4 % wächst und von 10.224,97 Millionen USD im Jahr 2022 auf 18.071,10 Millionen USD im Jahr 2030 ansteigen dürfte.
|
Berichtsmetrik |
Details |
|
Prognosezeitraum |
2023 bis 2030 |
|
Basisjahr |
2022 |
|
Historische Jahre |
2021 (anpassbar auf 2015–2020) |
|
Quantitative Einheiten |
Umsatz in Mio. USD |
|
Abgedeckte Segmente |
Nach Produkttyp (Gerät, Medikamente und andere), Krankheiten (Glaukom, Katarakt, altersbedingte Makuladegeneration, entzündliche Erkrankungen, Refraktionsstörungen und andere), Verschreibungsmodus (Generika und Markenprodukte), Medikamententyp (verschreibungspflichtig und rezeptfrei (OTC)), Verabreichungsweg (oral, topisch, injizierbar, lokal okular und andere), Endverbraucher (Krankenhäuser, Kliniken, häusliche Pflege und andere), Vertriebskanal (direkte Ausschreibung, Einzelhandelsverkauf und andere) |
|
Abgedeckte Länder |
China, Japan, Südkorea, Indien, Australien, Singapur, Thailand, Malaysia, Indonesien, Philippinen, Vietnam und der Rest des asiatisch-pazifischen Raums |
|
Abgedeckte Marktteilnehmer |
Alcon, Regeneron Pharmaceuticals Inc., Johnson & Johnson, Inc., Reichert, Inc., Novartis AG, Bausch & Lomb Incorporated, HOYA Corporation., The Cooper Companies Inc., Santen Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, Carl Zeiss Meditec AG, AbbVie Inc., EssilorLuxottica, NIDEK CO., LTD., TOPCON CORPORATION, Glaukos Corporation., STAAR SURGICAL, Metall Zug AG, Sun Pharmaceutical Industries Ltd., Lumenis Be Ltd., Pfizer Inc. und Ziemer Ophthalmic Systems AG |
Marktdefinition
Die Augenheilkunde ist ein Zweig der Medizin, der sich mit der Anatomie, Physiologie, Behandlung und Chirurgie der Sehbahnen des Auges, einschließlich der umgebenden Bereiche und der visuellen Aspekte des Gehirns, befasst. Ophthalmische Geräte sind medizinische Geräte, die für Operationen, Diagnosen und Sehkorrekturen entwickelt wurden. Die Geräte gewannen aufgrund der hohen Prävalenz verschiedener Augenkrankheiten wie Glaukom, Katarakt und anderer Sehprobleme an Bedeutung und Einsatz. Ophthalmische Medikamente sind Medikamente, die speziell für die Behandlung verschiedener Augenkrankheiten entwickelt und verabreicht werden, darunter Farbenblindheit, diabetisches Makulaödem , Cytomegalovirus (CMV) und altersbedingte Makuladegeneration (AMD).
Dynamik des Augenheilkundemarktes
In diesem Abschnitt geht es um das Verständnis der Markttreiber, Vorteile, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:
Treiber
- Steigende Prävalenz von Augenerkrankungen und Augenschmerzen
Augenerkrankungen sind die Hauptursache für starke Augen- und Augenhöhlenschmerzen. Augenschmerzen treten auf der Oberfläche der Augen auf und gehen mit Symptomen wie Kratzen, Brennen oder Jucken einher. Dies kann mehrere Ursachen haben, darunter Reizung durch Fremdkörper, Infektionen oder Traumata. Wimpern oder Schmutzpartikel, Rauch, Staub oder aggressive Augenkosmetika sind die häufigsten Ursachen für Augenschmerzen, Rötungen und tränende Augen.
Die Häufigkeit von Augenschmerzen nimmt aufgrund der wachsenden chemischen Industrie und Umweltverschmutzung weltweit weiter zu. Chemische Verbrennungen und Blitzverbrennungen verursachen aufgrund von Reizungen der Augenoberfläche erhebliche und schwere Augenschmerzen. Augenlidentzündungen und Blepharitis führen zu starken Augenschmerzen, da sie die Augen und Talgdrüsen in der Umgebung empfindlicher machen. Der positive Faktor besagt, dass dies der Haupttreiber für den Augenheilkundemarkt im asiatisch-pazifischen Raum ist.
- Anstieg traumatischer Verletzungen
Traumatische Kopfverletzungen sind eine der Ursachen für Erkrankungen wie Sehnervenerkrankungen. Eine traumatische Verletzung ist eine körperliche Verletzung, die plötzlich mit einem gewissen Schweregrad auftritt. Ein Trauma kann durch eine Vielzahl äußerer Verletzungen verursacht werden. Die häufigsten Ursachen für traumatische Verletzungen sind unter anderem Verkehrsunfälle, Sportverletzungen und Gewalt, die auch zu schweren Augenerkrankungen führen können. Die Prävalenz solcher traumatischer Verletzungen ist weltweit hoch.
Solche traumatischen Verletzungen führen daher zu Sehnervenerkrankungen, die die Bevölkerung in diesen Jahren beeinträchtigen und mit der wachsenden Bevölkerung zunehmen. Daher wird erwartet, dass ein Anstieg traumatischer Verletzungen das Marktwachstum vorantreiben wird.
Gelegenheiten
-
Anstieg der Gesundheitsausgaben und des verfügbaren Einkommens
Die Gesundheitsausgaben und ihre Wachstumsrate im Laufe der Zeit werden von einer Vielzahl wirtschaftlicher und sozialer Faktoren beeinflusst, einschließlich der Finanzierungsvereinbarungen und der Organisationsstruktur des Gesundheitssystems.
Die Gesundheitsausgaben sind weltweit gestiegen, da das verfügbare Einkommen der Menschen in vielen Ländern zunimmt. Um den Bedarf der Bevölkerung zu decken, ergreifen Regierungsbehörden und Gesundheitsorganisationen zudem Initiativen zur Erhöhung der Gesundheitsausgaben.
Steigende Gesundheitsausgaben sind auch für weiteres Wirtschaftswachstum und Wachstum im Gesundheitssektor von Vorteil. Sie sind vor allem deshalb von Vorteil, weil sie die Entwicklung besserer und fortschrittlicherer medizinischer Produkte auf dem Markt erheblich beeinflussen. Daher kann der Anstieg der Gesundheitsausgaben eine große Chance für Marktwachstum darstellen.
-
Sensibilisierung für die Prävention von Augenkrankheiten
Verschiedene Organisationen wie die Weltgesundheitsorganisation (WHO) und ihre Mitgliedsstaaten, UN-Agenturen, Nichtregierungsorganisationen (NGOs) und der Privatsektor haben bedeutende Fortschritte bei der Prävention von Sehbehinderungen im Kampf gegen sichtbare Krankheiten erzielt. Aus diesem Grund ist der zweite Donnerstag im Oktober der Welttag des Sehens (World Sight Day, WSD), ein jährlich stattfindender Aktionstag, um die Aufmerksamkeit der asiatisch-pazifischen Region auf Blindheit und Sehbehinderungen zu lenken.
Daher ist zu erwarten, dass die Programme und Initiativen zur Reduzierung der Belastung durch Augenkrankheiten im Prognosezeitraum Wachstumschancen für den Augenheilkundemarkt im Asien-Pazifik-Raum schaffen werden.
Einschränkungen/Herausforderungen
- Hohe Kosten und Risiken im Zusammenhang mit Augenoperationen und -behandlungen
Die Kosten der Behandlung verschiedener Erkrankungen spielen auf dem Markt eine große Rolle. Die Behandlung von Sehnervenerkrankungen ist hochentwickelt, da die Prävalenz solcher Erkrankungen zunimmt; daher ist der Bedarf an solchen Produkten schließlich gestiegen, was wiederum die Behandlungskosten erhöht, was das Marktwachstum in den kommenden Jahren behindern kann.
Es gibt verschiedene Methoden zur Behandlung der Optikusneuritis. Einige davon sind Medikamente, die Patienten einnehmen können, wie Kortikosteroide wie Methylprednisolon, Prednison, Immunglobulin , Vitamin-B12-Spritzen und verschiedene andere Operationen. Damit sind einige Risiken verbunden.
Für einen Teil der Bevölkerung im ganzen Land ist es daher aufgrund der hohen Kosten schwierig, sich solchen Behandlungen zu unterziehen. Daher wird erwartet, dass die mit der Behandlung von Augenerkrankungen verbundenen hohen Kosten das Marktwachstum bremsen werden.
- Fachkräftemangel
Die Zahl der Augenärzte ist sowohl in Schwellen- als auch in Industrieländern gering. Für Entwicklungsländer sind die Prognosen jedoch etwas höher. Die Zahl der Augenärzte wächst kumulativ, aber nicht so schnell wie die Zahl der älteren Patienten im Alter von 60 Jahren oder älter, die eine verstärkte augenärztliche Versorgung benötigen. In den meisten Ländern besteht das Problem darin, dass die demografischen Veränderungen nicht mit der beruflichen Entwicklung Schritt halten. Es ist erforderlich, Augenpflegeteams auszubilden, um der aktuellen Zahl der Augenärzte weltweit gerecht zu werden. Der weltweit gestiegene Bedarf an Augenärzten spiegelt auch einen Anstieg der Diabetesfälle wider. Diabetiker sollten ihre Augen jährlich untersuchen lassen. Die steigende Nachfrage nach Augenärzten ist direkt proportional zur wachsenden geriatrischen Bevölkerung, da die Augenpflege ein integraler Bestandteil der Gesundheitsversorgung ist. Die Lücken im Zugang zur Versorgung können durch eine Kombination von Faktoren geschlossen werden, darunter effizientere Praxisstrukturen, Prozesse und angemessener Einsatz von Technologie.
Auswirkungen von COVID-19 auf den Ophthalmologiemarkt
Die COVID-19-Pandemie hatte große Auswirkungen auf die ophthalmologische und chirurgische Industrie. Branchenverbände im Bereich der ophthalmologischen und augenmedizinischen Produkte behaupten, dass die Lieferkette für Operations-, Diagnose- und Sehpflegeprodukte im asiatisch-pazifischen Raum erheblich beschädigt wurde, was sich auf den Endverbrauch des ophthalmologischen Marktes auswirkte. Der Verkauf von Sehpflegeprodukten im ersten Quartal 2020 verzögerte sich aufgrund logistischer und Transportprobleme erheblich. Auf der Nachfrageseite wächst der Markt, da Menschen nach dem Lockdown operiert werden müssen. Die Situation muss berücksichtigt werden und es müssen Notoperationen durchgeführt werden. Darüber hinaus ist das Marktwachstum auf der Angebotsseite negativ. Dies ist auf die Lockdown-Situationen in vielen Ländern zurückzuführen, in denen Diagnose-, Operations- und Sehpflegeinstrumente hergestellt werden.
Jüngste Entwicklungen
- Im Oktober 2022 gab Regeneron Pharmaceuticals, Inc. bekannt, dass die US-amerikanische Food and Drug Administration (FDA) den ergänzenden Biologics License Application (sBLA) für die Injektion von EYLEA (Aflibercept) zur Behandlung der Frühgeborenenretinopathie (ROP) bei Frühgeborenen zur vorrangigen Prüfung angenommen hat. Diese Entwicklung hilft dem Unternehmen unter anderem dabei, sein Markenimage auf dem Markt für Augenheilkunde zu entwickeln.
- Im Mai 2022 hat Reichert, Inc. seine neu gestaltete Website für Refraktometer und Analyseinstrumente mit einer deutlich verbesserten Benutzererfahrung gestartet
Marktumfang für Augenheilkunde im asiatisch-pazifischen Raum
Der asiatisch-pazifische Markt für Augenheilkunde ist segmentiert in Produkte, Krankheiten, Verschreibungsarten, Arzneimitteltypen, Verabreichungswege, Endverbraucher und Vertriebskanäle. Das Wachstum dieser Segmente hilft Ihnen bei der Analyse schwacher Wachstumssegmente in den Branchen und bietet den Benutzern einen wertvollen Marktüberblick und Markteinblicke, um strategische Entscheidungen zur Identifizierung der wichtigsten Marktanwendungen zu treffen.
Produkte
- Gerät
- Medikamente
- Sonstiges
Auf der Grundlage der Produkte ist der Markt für Augenheilkunde in Geräte, Medikamente und Sonstiges segmentiert.
Krankheiten
- Glaukom
- Katarakt
- Altersbedingte Makuladegeneration
- Entzündliche Erkrankungen
- Refraktive Störungen
- Sonstiges
Auf der Grundlage von Krankheiten wird der Markt für Augenheilkunde in Glaukom, Katarakt, altersbedingte Makuladegeneration, entzündliche Erkrankungen, Refraktionsstörungen und andere unterteilt.
Rezeptmodus
- Generisch
- Gebrandmarkt
Auf Grundlage der Verschreibungsart wird der Markt für Augenheilkunde in Generika und Markenprodukte segmentiert.
Arzneimitteltyp
- Rezept
- Over the Counter (OTC)
Auf der Grundlage der Arzneimittelart ist der Markt für Augenheilkunde in verschreibungspflichtige und rezeptfreie Arzneimittel (OTC) segmentiert.
Verabreichungsweg
- Oral
- Aktuell
- Injektionen
- Lokales Okular
- Sonstiges
Auf der Grundlage der Verabreichungsart ist der Markt für Augenheilkunde in orale, topische, injizierbare, lokale okulare und andere Mittel unterteilt.
Endbenutzer
- Krankenhäuser
- Kliniken
- Häusliche Gesundheitspflege
- Sonstiges
Auf der Grundlage des Endbenutzers ist der Markt für Augenheilkunde in Krankenhäuser, Kliniken, häusliche Pflege und andere unterteilt.
Vertriebskanal
- Direkte Ausschreibung
- Einzelhandelsumsätze
- Sonstiges
Auf der Grundlage der Vertriebskanäle wird der Markt für Augenheilkunde in Direktausschreibungen, Einzelhandelsverkäufe und Sonstige segmentiert.
Regionale Analyse/Einblicke zum Augenheilkundemarkt
Der Markt für Dichtungen im asiatisch-pazifischen Raum ist nach Produkten, Krankheiten, Verschreibungsarten, Arzneimitteltypen, Verabreichungswegen, Endverbrauchern und Vertriebskanälen segmentiert.
Die Regionen im Dichtungsmarkt im asiatisch-pazifischen Raum sind China, Japan, Südkorea, Indien, Australien, Singapur, Thailand, Malaysia, Indonesien, Philippinen, Vietnam und der restliche asiatisch-pazifische Raum.
Aufgrund des steigenden Bewusstseins der Verbraucher für die Vorteile augenchirurgischer Eingriffe und einer besseren Sehkraft wird China voraussichtlich den Augenheilkundemarkt im asiatisch-pazifischen Raum dominieren.
Der Länderabschnitt des Berichts enthält auch einzelne marktbeeinflussende Faktoren und Änderungen der Marktregulierung, die sich auf die aktuellen und zukünftigen Trends des Marktes auswirken. Datenpunktanalysen der nachgelagerten und vorgelagerten Wertschöpfungsketten, technische Trends, Porters Fünf-Kräfte-Analyse und Fallstudien sind einige der Hinweise, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Bereitstellung von Prognoseanalysen der Länderdaten werden auch die Präsenz und Verfügbarkeit von Marken aus dem asiatisch-pazifischen Raum und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken, die Auswirkungen inländischer Zölle und Handelsrouten berücksichtigt.
Wettbewerbsumfeld und Asien-Pazifik-Augenheilkunde Marktanteilsanalyse
Die Wettbewerbslandschaft des Augenheilkundemarktes liefert Einzelheiten zu den Wettbewerbern. Zu den enthaltenen Einzelheiten gehören Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Präsenz im asiatisch-pazifischen Raum, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen auf den Augenheilkundemarkt im asiatisch-pazifischen Raum.
Zu den wichtigsten Akteuren auf diesem Markt zählen unter anderem Alcon, Regeneron Pharmaceuticals Inc., Johnson & Johnson, Inc., Reichert, Inc., Novartis AG, Bausch & Lomb Incorporated, HOYA Corporation., The Cooper Companies Inc., Santen Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, Carl Zeiss Meditec AG, AbbVie Inc., EssilorLuxottica, NIDEK CO., LTD., TOPCON CORPORATION, Glaukos Corporation., STAAR SURGICAL, Metall Zug AG, Sun Pharmaceutical Industries Ltd., Lumenis Be Ltd., Pfizer Inc. und Ziemer Ophthalmic Systems AG.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC OPHTHALMOLOGY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 ASIA PACIFIC OPHTHALMOLOGY MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 STRATEGIC INITIATIVES
7 ASIA PACIFIC OPHTHALMOLOGY MARKET, REGULATION
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING PREVALENCE OF OPHTHALMIC DISORDERS & OCULAR PAINS
8.1.2 INCREASING UNHYGIENIC & SEDENTARY LIFESTYLE
8.1.3 RISE IN TRAUMATIC INJURIES
8.1.4 RISE IN THE GERIATRIC POPULATION
8.2 RESTRAINTS
8.2.1 HIGH COST & RISKS ASSOCIATED WITH EYE SURGERY & TREATMENT
8.2.2 LACK OF HEALTH INSURANCE AMONGST THE POPULATION, ESPECIALLY WITHIN THE DEVELOPING COUNTRIES
8.2.3 SIDE EFFECTS ASSOCIATED WITH TREATMENT DRUGS
8.3 OPPORTUNITIES
8.3.1 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
8.3.3 RISING AWARENESS TO PREVENT THE BURDEN OF EYE DISEASES
8.4 CHALLENGE
8.4.1 LACK OF SKILLED PROFESSIONALS
8.4.2 STRINGENT RULES & REGULATIONS FOR PRODUCT APPROVAL
9 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY PRODUCTS
9.1 OVERVIEW
9.2 DEVICE
9.2.1 SURGICAL DEVICE
9.2.1.1 CATARACT SURGICAL DEVICES
9.2.1.2 OPHTHALMIC VISCOELASTIC DEVICES
9.2.1.2.1 PHACOEMULSIFICATION DEVICES
9.2.1.2.2 CATARACT SURGICAL LASERS
9.2.1.2.3 IOL INJECTORS
9.2.1.3 VITREORETINAL SURGICAL DEVICES
9.2.1.3.1 VITREORETINAL PACKS
9.2.1.3.2 VITRECTOMY MACHINES
9.2.1.3.3 VITRECTOMY PROBES
9.2.1.3.4 PHOTOCOAGULATION LASERS
9.2.1.3.5 ILLUMINATION DEVICES
9.2.1.4 REFRACTIVE SURGICAL DEVICES
9.2.1.4.1 FEMTOSECOND LASERS
9.2.1.4.2 EXCIMER LASERS
9.2.1.4.3 OTHER REFRACTIVE SURGICAL LASERS
9.2.1.5 GLAUCOMA SURGICAL DEVICES
9.2.1.5.1 GLAUCOMA DRAINAGE DEVICES
9.2.1.5.2 GLAUCOMA LASER SYSTEMS
9.2.1.5.3 MICRO INVASIVE GLAUCOMA SURGERY DEVICES
9.2.2 DIAGNOSTIC DEVICE
9.2.2.1 AUTOREFRACTORS & KERATOMETERS
9.2.2.2 TONOMETER
9.2.2.3 PHOROPTERS
9.2.2.4 RETINOSCOPES
9.2.2.5 OPHTHALMOSCOPES
9.2.2.6 PERIMETERS/VISUAL FIELD ANALYZERS
9.2.2.7 OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
9.2.2.7.1 A- SCAN IMAGING SYSTEM
9.2.2.7.2 B-SCAN IMAGING SYSTEM
9.2.2.7.3 PACHYMETERS
9.2.2.7.4 ULTRASOUND BIOMICROSCOPES
9.2.2.8 LENSMETERS
9.2.2.9 CORNEAL TOPOGRAPHY SYSTEMS
9.2.2.10 OPTICAL COHERENCE TOMOGRAPHY SCANNERS
9.2.2.11 FUNDUS CAMERAS
9.2.2.12 OPTICAL BIOMETRY SYSTEMS
9.2.2.13 SPECULAR MICROSCOPES
9.2.2.14 WAVEFRONT ABERROMETERS
9.2.2.15 CHART PROJECTORS
9.2.2.16 SLIT LAMPS
9.2.3 OPHTHALMIC SURGICAL ACCESSORIES
9.2.3.1 SURGICAL INSTRUMENTS & KITS
9.2.3.2 OPHTHALMIC FORCEPS
9.2.3.3 OPHTHALMIC SPATULA
9.2.3.4 OPHTHALMIC TIPS AND HANDLES
9.2.3.5 OPHTHALMIC CANNULAS
9.2.3.6 OPHTHALMIC SCISSORS
9.2.3.7 OTHERS SURGICAL ACCESSORIES
9.2.4 OPHTHALMIC MICROSCOPES
9.3 DRUGS
9.3.1 ANTI-INFLAMMATION DRUGS
9.3.1.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
9.3.1.2 STEROIDAL ANTI-INFLAMMATORY DRUGS
9.3.2 ALLERGIC CONJUNCTIVITIS
9.3.3 DRY EYE DRUGS
9.3.4 RETINAL DISORDER DRUGS
9.3.5 ANTI-GLAUCOMA DRUGS
9.3.5.1 MIOTICS
9.3.5.1.1 PILOCARPINE
9.3.5.1.2 ESERINE
9.3.5.2 BETA ADRENERGIC ANTAGONISTS
9.3.5.2.1 TIMOLAL MALEATE
9.3.5.2.2 BETAXOLOL
9.3.5.3 PROSTAGLANDIN ANALOGS
9.3.5.3.1 LATANOPROST
9.3.5.3.2 BIMATOPROST
9.3.5.3.3 TRAVOPROST
9.3.5.3.4 TAFLUPROST
9.3.5.3.5 LATANOPROSTENE
9.3.5.4 ALPHA ADRENERGIC AGONISTS
9.3.5.4.1 EPINEPHRINE
9.3.5.4.2 DEPIVEPRINE
9.3.5.5 ANTI-VEGF DRUGS
9.3.5.5.1 RANIBIZUMAB
9.3.5.5.2 BEVACIZUMAB
9.3.6 OTHERS
9.4 OTHERS
9.4.1 VISION CARE PRODUCTS
9.4.1.1 SPECTACLES
9.4.1.2 CONTACT LENSES
9.4.1.2.1 SOFT CONTACT LENSES
9.4.1.2.2 HYBRID CONTACT LENSES
9.4.1.2.3 RIGID GAS PERMEABLE LENSES
9.4.2 OTHERS
10 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY DISEASES
10.1 OVERVIEW
10.2 INFLAMMATORY DISEASES
10.3 CATARACT
10.4 REFRACTIVE DISORDERS
10.5 GLAUCOMA
10.6 AGE-RELATED MACULAR DEGENERATION
10.7 OTHERS
11 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE
11.1 OVERVIEW
11.2 BRANDED
11.3 GENERIC
12 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 OVER THE COUNTER
12.3 PRESCRIPTION
13 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 TOPICAL
13.2.1 EYE DROPS
13.2.2 EYE SOLUTION
13.2.3 CREAM & OINTMENTS
13.2.4 GEL
13.2.5 OTHERS
13.3 ORAL
13.3.1 TABLET
13.3.2 CAPSULES
13.3.3 OTHERS
13.4 LOCAL OCULAR
13.4.1 SUBCONJUNCTIVAL
13.4.2 INTRAVITREAL
13.4.3 RETROBULBAR
13.4.4 INTRACAMERAL
13.5 INJECTABLE
13.5.1 INTRAMUSCULAR
13.5.2 INTRAVENOUS
13.5.3 OTHERS
13.6 OTHERS
14 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY END USER
14.1 OVERVIEW
14.2 CLINICS
14.3 HOSPITALS
14.4 HOMECARE SETTINGS
14.5 OTHERS
15 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 RETAIL SHOPS
15.2.2 HOSPITAL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
15.4 OTHERS
16 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY GEOGRAPHY
16.1 ASIA-PACIFIC
16.1.1 CHINA
16.1.2 JAPAN
16.1.3 INDIA
16.1.4 AUSTRALIA
16.1.5 SOUTH KOREA
16.1.6 THAILAND
16.1.7 SINGAPORE
16.1.8 INDONESIA
16.1.9 MALAYSIA
16.1.10 PHILIPPINES
16.1.11 VIETNAM
16.1.12 REST OF ASIA-PACIFIC
17 ASIA PACIFIC OPHTHALMOLOGY MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 ALCON
19.1.1 COMPANY SNAPSHOT
19.1.2 RECENT FINANCIALS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 REGENERON PHARMACEUTICALS INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 RECENT FINANCIALS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 JOHNSON & JOHNSON SERVICES, INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 RECENT FINANCIALS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 REICHERT, INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 COMPANY SHARE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENT
19.5 NOVARTIS AG
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ABBVIE INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 RECENT FINANCIALS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 BAUSCH & LOMB INCORPORATED
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 CARL ZEISS MEDITEC AG
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 ESSILORLUXOTTICA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMEN
19.1 F. HOFFMANN- LA ROCHE LTD
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 GLAUKOS
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 HEIDELBERG ENGINEERING GMBH
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 HOYA CORPORATION
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 LUMENIS BE LTD.
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 METALL ZUG AG
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 NEOVISION
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 NIDEK CO., LTD.
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 SANTEN PHARMACEUTICAL CO., LTD.
19.19.1 COMPANY SNAPSHOT
19.19.2 RECENT FINANCIALS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 RECENT FINANCIALS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 STAAR SURGICAL
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 THE COOPER COMPANIES INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
19.23 TOPCON CORPORATION
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 VISIONIX
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENT
19.25 ZIEMER OPHTHALMIC SYSTEMS AG
19.25.1 COMPANY SNAPSHOT
19.25.2 PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2 ASIA PACIFIC DEVICE IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 ASIA PACIFIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 4 ASIA PACIFIC SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 5 ASIA PACIFIC OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 6 ASIA PACIFIC VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 7 ASIA PACIFIC REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 8 ASIA PACIFIC GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 9 ASIA PACIFIC DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 10 ASIA PACIFIC OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 11 ASIA PACIFIC OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 12 ASIA PACIFIC DRUGS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 ASIA PACIFIC DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 14 ASIA PACIFIC ANTI INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 15 ASIA PACIFIC ANTI GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 16 ASIA PACIFIC MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 17 ASIA PACIFIC BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 18 ASIA PACIFIC PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 19 ASIA PACIFIC ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 20 ASIA PACIFIC ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 21 ASIA PACIFIC OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 ASIA PACIFIC OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 23 ASIA PACIFIC VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 24 ASIA PACIFIC CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION))
TABLE 25 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY DISEASES 2021-2030 (USD MILLION)
TABLE 26 ASIA PACIFIC INFLAMMATORY DISEASES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 ASIA PACIFIC CATARACT IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 ASIA PACIFIC REFRACTIVE DISORDERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 ASIA PACIFIC GLAUCOMA IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 ASIA PACIFIC OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 33 ASIA PACIFIC BRANDED IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 ASIA PACIFIC GENERIC IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY DRUG TYPE 2021-2030 (USD MILLION)
TABLE 36 ASIA PACIFIC OVER THE COUNTER IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 ASIA PACIFIC PRESCRIPTION IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 39 ASIA PACIFIC TOPICAL IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 ASIA PACIFIC TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 41 ASIA PACIFIC ORAL IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 ASIA PACIFIC ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 43 ASIA PACIFIC LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 ASIA PACIFIC LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 45 ASIA PACIFIC INJECTABLES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 ASIA PACIFIC INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 47 ASIA PACIFIC OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 49 ASIA PACIFIC CLINICS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 ASIA PACIFIC HOSPITALS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 ASIA PACIFIC HOME HEALTHCARE IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 ASIA PACIFIC OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 ASIA PACIFIC OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 54 ASIA PACIFIC RETAIL SALES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 ASIA PACIFIC RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL 2021-2030 (USD MILLION)
TABLE 56 ASIA PACIFIC DIRECT TENDER IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 ASIA PACIFIC OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 ASIA-PACIFIC OPHTHALMOLOGY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 59 ASIA-PACIFIC OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 60 ASIA-PACIFIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 61 ASIA-PACIFIC SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 62 ASIA-PACIFIC OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 63 ASIA-PACIFIC VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 64 ASIA-PACIFIC REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 65 ASIA-PACIFIC GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 66 ASIA-PACIFIC DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 67 ASIA-PACIFIC OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 68 ASIA-PACIFIC OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 69 ASIA-PACIFIC DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 70 ASIA-PACIFIC ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 71 ASIA-PACIFIC ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 72 ASIA-PACIFIC MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 73 ASIA-PACIFIC BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 74 ASIA-PACIFIC PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 75 ASIA-PACIFIC ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 76 ASIA-PACIFIC ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 77 ASIA-PACIFIC OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 78 ASIA-PACIFIC VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 79 ASIA-PACIFIC CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 80 ASIA-PACIFIC OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 81 ASIA-PACIFIC OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 82 ASIA-PACIFIC OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 83 ASIA-PACIFIC OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 84 ASIA-PACIFIC TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 85 ASIA-PACIFIC ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 86 ASIA-PACIFIC LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 87 ASIA-PACIFIC INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 88 ASIA-PACIFIC OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 89 ASIA-PACIFIC OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 90 ASIA-PACIFIC RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 91 CHINA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 92 CHINA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 93 CHINA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 94 CHINA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 95 CHINA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 96 CHINA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 97 CHINA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 98 CHINA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 99 CHINA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 100 CHINA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 101 CHINA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 102 CHINA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 103 CHINA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 104 CHINA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 105 CHINA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 106 CHINA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 107 CHINA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 108 CHINA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 109 CHINA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 110 CHINA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 111 CHINA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 112 CHINA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 113 CHINA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 114 CHINA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 115 CHINA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 116 CHINA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 117 CHINA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 118 CHINA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 119 CHINA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 120 CHINA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 121 CHINA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 122 CHINA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 123 JAPAN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 124 JAPAN DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 125 JAPAN SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 126 JAPAN OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 127 JAPAN VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 128 JAPAN REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 129 JAPAN GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 130 JAPAN DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 131 JAPAN OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 132 JAPAN OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 133 JAPAN DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 134 JAPAN ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 135 JAPAN ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 136 JAPAN MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 137 JAPAN BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 138 JAPAN PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 139 JAPAN ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 140 JAPAN ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 141 JAPAN OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 142 JAPAN VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 143 JAPAN CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 144 JAPAN OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 145 JAPAN OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 146 JAPAN OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 147 JAPAN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 148 JAPAN TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 149 JAPAN ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 150 JAPAN LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 151 JAPAN INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 152 JAPAN OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 153 JAPAN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 154 JAPAN RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 155 INDIA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 156 INDIA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 157 INDIA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 158 INDIA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 159 INDIA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 160 INDIA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 161 INDIA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 162 INDIA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 163 INDIA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 164 INDIA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 165 INDIA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 166 INDIA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 167 INDIA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 168 INDIA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 169 INDIA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 170 INDIA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 171 INDIA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 172 INDIA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 173 INDIA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 174 INDIA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 175 INDIA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 176 INDIA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 177 INDIA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 178 INDIA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 INDIA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 180 INDIA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 181 INDIA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 182 INDIA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 183 INDIA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 184 INDIA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 185 INDIA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 186 INDIA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 187 AUSTRALIA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 188 AUSTRALIA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 189 AUSTRALIA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 190 AUSTRALIA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 191 AUSTRALIA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 192 AUSTRALIA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 193 AUSTRALIA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 194 AUSTRALIA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 195 AUSTRALIA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 196 AUSTRALIA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 197 AUSTRALIA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 198 AUSTRALIA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 199 AUSTRALIA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 200 AUSTRALIA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 201 AUSTRALIA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 202 AUSTRALIA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 203 AUSTRALIA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 204 AUSTRALIA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 205 AUSTRALIA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 206 AUSTRALIA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 207 AUSTRALIA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 208 AUSTRALIA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 209 AUSTRALIA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 210 AUSTRALIA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 211 AUSTRALIA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 212 AUSTRALIA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 213 AUSTRALIA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 214 AUSTRALIA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 215 AUSTRALIA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 216 AUSTRALIA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 217 AUSTRALIA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 218 AUSTRALIA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 219 SOUTH KOREA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 220 SOUTH KOREA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 221 SOUTH KOREA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 222 SOUTH KOREA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 223 SOUTH KOREA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 224 SOUTH KOREA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 225 SOUTH KOREA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 226 SOUTH KOREA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 227 SOUTH KOREA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 228 SOUTH KOREA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 229 SOUTH KOREA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 230 SOUTH KOREA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 231 SOUTH KOREA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 232 SOUTH KOREA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 233 SOUTH KOREA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 234 SOUTH KOREA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 235 SOUTH KOREA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 236 SOUTH KOREA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 237 SOUTH KOREA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 238 SOUTH KOREA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 239 SOUTH KOREA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 240 SOUTH KOREA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 241 SOUTH KOREA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 242 SOUTH KOREA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 243 SOUTH KOREA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 244 SOUTH KOREA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 245 SOUTH KOREA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 246 SOUTH KOREA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 247 SOUTH KOREA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 248 SOUTH KOREA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 249 SOUTH KOREA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 250 SOUTH KOREA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 251 THAILAND OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 252 THAILAND DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 253 THAILAND SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 254 THAILAND OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 255 THAILAND VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 256 THAILAND REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 257 THAILAND GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 258 THAILAND DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 259 THAILAND OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 260 THAILAND OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 261 THAILAND DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 262 THAILAND ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 263 THAILAND ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 264 THAILAND MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 265 THAILAND BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 266 THAILAND PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 267 THAILAND ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 268 THAILAND ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 269 THAILAND OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 270 THAILAND VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 271 THAILAND CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 272 THAILAND OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 273 THAILAND OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 274 THAILAND OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 275 THAILAND OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 276 THAILAND TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 277 THAILAND ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 278 THAILAND LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 279 THAILAND INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 280 THAILAND OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 281 THAILAND OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 282 THAILAND RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 283 SINGAPORE OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 284 SINGAPORE DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 285 SINGAPORE SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 286 SINGAPORE OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 287 SINGAPORE VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 288 SINGAPORE REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 289 SINGAPORE GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 290 SINGAPORE DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 291 SINGAPORE OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 292 SINGAPORE OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 293 SINGAPORE DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 294 SINGAPORE ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 295 SINGAPORE ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 296 SINGAPORE MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 297 SINGAPORE BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 298 SINGAPORE PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 299 SINGAPORE ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 300 SINGAPORE ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 301 SINGAPORE OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 302 SINGAPORE VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 303 SINGAPORE CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 304 SINGAPORE OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 305 SINGAPORE OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 306 SINGAPORE OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 307 SINGAPORE OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 308 SINGAPORE TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 309 SINGAPORE ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 310 SINGAPORE LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 311 SINGAPORE INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 312 SINGAPORE OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 313 SINGAPORE OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 314 SINGAPORE RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 315 INDONESIA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 316 INDONESIA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 317 INDONESIA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 318 INDONESIA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 319 INDONESIA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 320 INDONESIA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 321 INDONESIA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 322 INDONESIA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 323 INDONESIA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 324 INDONESIA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 325 INDONESIA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 326 INDONESIA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 327 INDONESIA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 328 INDONESIA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 329 INDONESIA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 330 INDONESIA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 331 INDONESIA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 332 INDONESIA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 333 INDONESIA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 334 INDONESIA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 335 INDONESIA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 336 INDONESIA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 337 INDONESIA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 338 INDONESIA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 339 INDONESIA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 340 INDONESIA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 341 INDONESIA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 342 INDONESIA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 343 INDONESIA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 344 INDONESIA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 345 INDONESIA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 346 INDONESIA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 347 MALAYSIA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 348 MALAYSIA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 349 MALAYSIA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 350 MALAYSIA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 351 MALAYSIA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 352 MALAYSIA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 353 MALAYSIA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 354 MALAYSIA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 355 MALAYSIA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 356 MALAYSIA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 357 MALAYSIA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 358 MALAYSIA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 359 MALAYSIA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 360 MALAYSIA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 361 MALAYSIA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 362 MALAYSIA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 363 MALAYSIA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 364 MALAYSIA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 365 MALAYSIA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 366 MALAYSIA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 367 MALAYSIA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 368 MALAYSIA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 369 MALAYSIA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 370 MALAYSIA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 371 MALAYSIA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 372 MALAYSIA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 373 MALAYSIA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 374 MALAYSIA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 375 MALAYSIA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 376 MALAYSIA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 377 MALAYSIA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 378 MALAYSIA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 379 PHILIPPINES OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 380 PHILIPPINES DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 381 PHILIPPINES SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 382 PHILIPPINES OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 383 PHILIPPINES VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 384 PHILIPPINES REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 385 PHILIPPINES GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 386 PHILIPPINES DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 387 PHILIPPINES OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 388 PHILIPPINES OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 389 PHILIPPINES DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 390 PHILIPPINES ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 391 PHILIPPINES ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 392 PHILIPPINES MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 393 PHILIPPINES BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 394 PHILIPPINES PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 395 PHILIPPINES ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 396 PHILIPPINES ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 397 PHILIPPINES OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 398 PHILIPPINES VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 399 PHILIPPINES CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 400 PHILIPPINES OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 401 PHILIPPINES OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 402 PHILIPPINES OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 403 PHILIPPINES OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 404 PHILIPPINES TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 405 PHILIPPINES ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 406 PHILIPPINES LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 407 PHILIPPINES INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 408 PHILIPPINES OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 409 PHILIPPINES OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 410 PHILIPPINES RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 411 VIETNAM OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 412 VIETNAM DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 413 VIETNAM SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 414 VIETNAM OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 415 VIETNAM VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 416 VIETNAM REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 417 VIETNAM GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 418 VIETNAM DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 419 VIETNAM OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 420 VIETNAM OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 421 VIETNAM DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 422 VIETNAM ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 423 VIETNAM ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 424 VIETNAM MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 425 VIETNAM BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 426 VIETNAM PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 427 VIETNAM ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 428 VIETNAM ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 429 VIETNAM OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 430 VIETNAM VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 431 VIETNAM CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 432 VIETNAM OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 433 VIETNAM OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 434 VIETNAM OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 435 VIETNAM OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 436 VIETNAM TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 437 VIETNAM ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 438 VIETNAM LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 439 VIETNAM INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 440 VIETNAM OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 441 VIETNAM OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 442 VIETNAM RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 443 REST OF ASIA-PACIFIC OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
Abbildungsverzeichnis
FIGURE 1 ASIA PACIFIC OPHTHALMOLOGY MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC OPHTHALMOLOGY MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC OPHTHALMOLOGY MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC OPHTHALMOLOGY MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC OPHTHALMOLOGY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC OPHTHALMOLOGY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC OPHTHALMOLOGY MARKET: DBMR POSITION GRID
FIGURE 8 ASIA PACIFIC OPHTHALMOLOGY MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ASIA PACIFIC OPHTHALMOLOGY MARKET: END USER COVERAGE GRID
FIGURE 10 ASIA PACIFIC OPHTHALMOLOGY MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF OPHTHALMIC DISORDERS& INCREASING GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE ASIA PACIFIC OPHTHALMOLOGY MARKET FROM 2022 TO 2029
FIGURE 12 THE DEVICE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ASIA PACIFIC OPHTHALMOLOGY MARKET FROM 2022 TO 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC OPHTHALMOLOGY MARKET
FIGURE 14 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY PRODUCTS, 2022
FIGURE 15 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY PRODUCTS, 2023-2030 (USD MILLION)
FIGURE 16 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY PRODUCTS, CAGR (2023-2030)
FIGURE 17 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 18 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY DISEASES, 2022
FIGURE 19 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY DISEASES, 2023-2030 (USD MILLION)
FIGURE 20 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY DISEASES, CAGR (2023-2030)
FIGURE 21 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE ,2022
FIGURE 23 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, 2023-2030 (USD MILLION)
FIGURE 24 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, CAGR (2023-2030)
FIGURE 25 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY DRUG TYPE ,2022
FIGURE 27 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 28 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 29 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 30 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 31 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 32 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 33 ASIA PACIFIC OPHTHALMOLOGY MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 34 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY END USER, 2022
FIGURE 35 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 36 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 39 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 40 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 41 ASIA PACIFIC OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 ASIA-PACIFIC OPHTHALMOLOGY MARKET: SNAPSHOT (2022)
FIGURE 43 ASIA-PACIFIC OPHTHALMOLOGY MARKET: BY COUNTRY (2022)
FIGURE 44 ASIA-PACIFIC OPHTHALMOLOGY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 45 ASIA-PACIFIC OPHTHALMOLOGY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 46 ASIA-PACIFIC OPHTHALMOLOGY MARKET: PRODUCTS (2023-2030)
FIGURE 47 ASIA PACIFIC OPHTHALMOLOGY MARKET: COMPANY SHARE 2022 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
